Literature DB >> 12975392

The CARDia trial protocol.

D Smith.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12975392      PMCID： PMC1767914          DOI： 10.1136/heart.89.10.1125

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  13 in total

Review 1.  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.

Authors:  S T Brookes; E Whitley; T J Peters; P A Mulheran; M Egger; G Davey Smith
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

2.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)

Authors: 
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

3.  Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.

Authors:  A Abizaid; M A Costa; M Centemero; A S Abizaid; V M Legrand; R V Limet; G Schuler; F W Mohr; W Lindeboom; A G Sousa; J E Sousa; B van Hout; P G Hugenholtz; F Unger; P W Serruys
Journal:  Circulation       Date:  2001-07-31       Impact factor: 29.690

4.  A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST)

Authors:  S B King; N J Lembo; W S Weintraub; A S Kosinski; H X Barnhart; M H Kutner; N P Alazraki; R A Guyton; X Q Zhao
Journal:  N Engl J Med       Date:  1994-10-20       Impact factor: 91.245

5.  The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics.

Authors:  S P Marso; S G Ellis; M Tuzcu; P L Whitlow; I Franco; R E Raymond; E J Topol
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

6.  Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.

Authors:  T Takagi; T Akasaka; A Yamamuro; Y Honda; T Hozumi; S Morioka; K Yoshida
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

7.  Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting.

Authors:  Zoltán Szabó; Erik Håkanson; Rolf Svedjeholm
Journal:  Ann Thorac Surg       Date:  2002-09       Impact factor: 4.330

8.  Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure.

Authors:  Doron Aronson
Journal:  Med Hypotheses       Date:  2002-09       Impact factor: 1.538

9.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.

Authors:  B Stein; W S Weintraub; S P Gebhart; C L Cohen-Bernstein; R Grosswald; H A Liberman; J S Douglas; D C Morris; S B King
Journal:  Circulation       Date:  1995-02-15       Impact factor: 29.690

10.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245
View more
  2 in total

1.  Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.

Authors:  P de Araujo Goncalves; R Seabra-Gomes; R Teles; M Almeida; C Aguiar; L Raposo; J Ferreira; F Pereira Machado
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

2.  SMART: Study protocol for a sequential multiple assignment randomized controlled trial to optimize weight loss management.

Authors:  Angela Fidler Pfammatter; Inbal Nahum-Shani; Margaret DeZelar; Laura Scanlan; H Gene McFadden; Juned Siddique; Donald Hedeker; Bonnie Spring
Journal:  Contemp Clin Trials       Date:  2019-05-23       Impact factor: 2.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.